Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) Invested Capital (2016 - 2025)

United Therapeutics' Invested Capital history spans 17 years, with the latest figure at $7.1 billion for Q4 2025.

  • For Q4 2025, Invested Capital rose 5.22% year-over-year to $7.1 billion; the TTM value through Dec 2025 reached $7.1 billion, up 5.22%, while the annual FY2025 figure was $7.1 billion, 5.22% up from the prior year.
  • Invested Capital for Q4 2025 was $7.1 billion at United Therapeutics, up from $6.6 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $7.2 billion in Q2 2025 and bottomed at $3.4 billion in Q1 2021.
  • The 5-year median for Invested Capital is $5.6 billion (2023), against an average of $5.4 billion.
  • The largest annual shift saw Invested Capital skyrocketed 33.11% in 2023 before it increased 1.37% in 2025.
  • A 5-year view of Invested Capital shows it stood at $4.0 billion in 2021, then increased by 21.16% to $4.8 billion in 2022, then soared by 33.11% to $6.4 billion in 2023, then increased by 5.63% to $6.7 billion in 2024, then rose by 5.22% to $7.1 billion in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Invested Capital are $7.1 billion (Q4 2025), $6.6 billion (Q3 2025), and $7.2 billion (Q2 2025).